Fisher & Paykel Healthcare Corporation Ltd
ASX:FPH
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| NZ |
|
Fisher & Paykel Healthcare Corporation Ltd
NZX:FPH
|
23.1B NZD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
192B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.6B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
136.5B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
131.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
112.1B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.6B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
39.5B USD |
Loading...
|
Market Distribution
| Min | -127.6% |
| 30th Percentile | 37.1% |
| Median | 51% |
| 70th Percentile | 64.7% |
| Max | 107.2% |
Other Profitability Ratios
Fisher & Paykel Healthcare Corporation Ltd
Glance View
Nestled in the heart of New Zealand, Fisher & Paykel Healthcare Corporation Ltd. has emerged as a formidable player in the global healthcare market, largely due to its innovative spirit and relentless focus on respiratory care solutions. Originally part of Fisher & Paykel Industries, the healthcare division carved its own path in 2001, quickly becoming synonymous with high-quality medical devices. The company’s journey can be compared to a constant rhythm of innovation, particularly in areas that address obstructive sleep apnea, acute respiratory distress, and surgical humidification. Its revenue streams are primarily bolstered by a diverse array of products, including sleep apnea masks, humidifier systems for intensive care units, and related respiratory accessories. These offerings are not just technological marvels but are designed to improve patient outcomes and their quality of life, which resonates well with healthcare providers worldwide. Over the years, Fisher & Paykel Healthcare has strategically expanded its operations beyond its Kiwi roots, anchoring its presence in over 120 countries. This global footprint, coupled with a robust pipeline of patented products, enables sustained revenue growth and stability. The company’s financial health is driven by a business model that emphasizes research and development, ensuring that it remains at the forefront of medical innovation. By fostering close relationships with healthcare professionals and institutions, Fisher & Paykel not only gains invaluable insights to refine its products but also cultivates a loyal customer base. This enduring approach cements its position not only as a leader in the healthcare sector but also as a trusted partner in the critical mission to enhance patient care worldwide.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Fisher & Paykel Healthcare Corporation Ltd is 63.4%, which is above its 3-year median of 61%.
Over the last 3 years, Fisher & Paykel Healthcare Corporation Ltd’s Gross Margin has increased from 61% to 63.4%. During this period, it reached a low of 59.4% on Mar 31, 2023 and a high of 63.4% on Sep 30, 2025.